From ACC 2024 – STEP HFpEF DM: Semaglutide 2.4 mg Improves Functional Status, Symptoms in Patients with Diabetes, HFpEF

From ACC 2024 – STEP HFpEF DM: Semaglutide 2.4 mg Improves Functional Status, Symptoms in Patients with Diabetes, HFpEF New data presented at the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions underlines the benefits of semaglutide in patients with heart failure with preserved ejection fraction (HFpEF), specifically those with concomitant diabetes mellitus and obesity.1 Presented by […]

Newly reported from ACC 2024: Inclisiran First Strategy Safe, Effective for LDL-C Control in ASCVD Patients

Newly reported from ACC 2024: Inclisiran First Strategy Safe, Effective for LDL-C Control in ASCVD Patients Use of an inclisiran (Leqvio) first implementation strategy among patients with atherosclerotic cardiovascular disease and an LDL-C at 70 or greater was associated with a significant reduction in LDL-C relative to usual care, without incurring safety concerns or limiting statin use, according to […]

Newscasting from ACC 2024: AEGIS-II Misses Primary Endpoint, Suggests Potential for CSL112 in Hyperlipidemia

Newscasting from ACC 2024: AEGIS-II Misses Primary Endpoint, Suggests Potential for CSL112 in Hyperlipidemia Use of CSL112, a 6 mg infusion of apolipoprotein A-I (ApoA-1), was not associated with a reduction in major adverse cardiovascular events in the AEGIS-II trial, according to data presented at the American College of Cardiology (ACC 2024) Annual Scientific Session. A phase 3 […]

Broadcasting from ACC 2024: Empagliflozin Misses Primary Endpoint in Post-MI Patient Population, EMPACT-MI Trial

Broadcasting from ACC 2024: Empagliflozin Misses Primary Endpoint in Post-MI Patient Population, EMPACT-MI Trial Use of empagliflozin did not lead to a significant reduction in the composite of hospitalizations for heart failure or all-cause mortality in patients at increased risk for heart failure after acute myocardial infarction, according to results of the EMPACT-MI trial. Presented at the American […]

ACC 2024: Short Sleep Duration Linked to Risk of Developing Hypertension

ACC 2024: Short Sleep Duration Linked to Risk of Developing Hypertension Short sleep duration is associated with an increased risk of developing hypertension, according to a study scheduled for presentation at the annual meeting of the American College of Cardiology, held from April 6 to 8 in Atlanta. Aayushi Sood, M.D., from The Wright Center […]

From ACC 2024: Small but Significant Risk for Cardiomyopathy Seen With ADHD Meds

From ACC 2024: Small but Significant Risk for Cardiomyopathy Seen With ADHD Meds Young adults prescribed stimulant medications for attention-deficit/hyperactivity disorder (ADHD) have an increased risk for cardiomyopathy, with the risk increasing with duration of treatment, according to a study scheduled for presentation at the annual meeting of the American College of Cardiology, held from […]

Broadcasted from ACC 2024: Coronary Artery Calcium Progression May Accelerate After Menopause

Broadcasted from ACC 2024: Coronary Artery Calcium Progression May Accelerate After Menopause Postmenopausal changes may accelerate coronary artery calcium (CAC) progression in women, according to a study presented at the annual meeting of the American College of Cardiology, held from April 6 to 8 in Atlanta. Ella Ishaaya, M.D., from Harbor-UCLA Medical Center in Torrance, […]

News Coverage from ACC 2024: AI-Based Video Biomarker Detects Aortic Stenosis Progression

News Coverage from ACC 2024: AI-Based Video Biomarker Detects Aortic Stenosis Progression A video-based artificial intelligence (AI) biomarker (Digital Aortic Stenosis [AS] Severity index [DASSi]) can detect severe AS development and progression among patients undergoing echocardiography or cardiac magnetic resonance imaging, according to a study published online April 6 in JAMA Cardiology to coincide with the annual […]

ACC 2024: Empagliflozin Cuts Heart Failure Hospitalization Risk After AMI

ACC 2024: Empagliflozin Cuts Heart Failure Hospitalization Risk After AMI For patients with acute myocardial infarction at risk for heart failure, empagliflozin reduces the risk for heart failure hospitalization, according to a study published online April 6 in Circulation to coincide with the annual meeting of the American College of Cardiology, held from April 6 to 8 […]